Welcome to the 6th Microbiome Movement - Drug Development Summit Europe

As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.

The 6th Microbiome Movement – Drug Development Summit Europe will return online to unite leading scientists and industry partners surrounding the microbiome to pursue the causal role of the microbiome in disease, with the aim to obtain the first EMA-approved microbiome-targeted therapeutic from predictable modes of action and consistent clinical outcomes. Join us to explore the progress made in the last 12 months, and uncover where this microbiome space is heading!

50+ Expert Speakers Included

Charles Bundinof

Strain Discovery and Microbiome Science Lead

IFF

Denise Kelly

Investment Advisor

Seventure

Duncan Peyton

CEO

4D Pharma PLC

Hervé Affagard

CEO

MaaT Pharma

John Hambor

Director, Research Beyond Borders

Boehringer Ingleheim

Kristin Wannerberger

Director R&D Alliance Management

Ferring Pharmaceuticals

Mike Ramonas

CEO

Microbiotica

Yogesh Mudaliar

Scientist Drug Product Development

Takeda

Hear What Our Customers Say

"As a newcomer to the microbiome field, this conference provided an excellent overview.”

Richard Shanksky
Seres  Therapeutics

“It was a great conference to effectively learn the current trends in microbiome drug development around the world.”

Nanae Izumi
Daiichi Sankyo

Confirmed Partners for 2022 Included

Boston Analytical
ArrantaBio_Logo_RGB
BACTHERA_logo_RGB_black (002)
Microba-Logo_Colour
Atlantia clinical trials
Biose Industrie
1519865705643
ProDigest
R (2)
logo-biofortis_couleur_HD
Basic CMYK
MERCK_LOGO_RRed_4C

Other Events In The Series